BioInvent International (0H22) Stock Overview
A clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0H22 from our risk checks.
0H22 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 30.83 |
| 52 Week High | SEK 49.00 |
| 52 Week Low | SEK 23.75 |
| Beta | -0.089 |
| 1 Month Change | -19.62% |
| 3 Month Change | -20.09% |
| 1 Year Change | -23.23% |
| 3 Year Change | -31.80% |
| 5 Year Change | -30.57% |
| Change since IPO | -95.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H22 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -16.9% | 0.6% | 2.7% |
| 1Y | -23.2% | 10.9% | 19.1% |
Return vs Industry: 0H22 underperformed the UK Biotechs industry which returned 10.9% over the past year.
Return vs Market: 0H22 underperformed the UK Market which returned 19.1% over the past year.
Price Volatility
| 0H22 volatility | |
|---|---|
| 0H22 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0H22 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0H22's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 122 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1 clinical trial for the treatment of solid tumors. It has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; collaboration and supply agreement with MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; and licensing agreement with CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers.
BioInvent International AB (publ) Fundamentals Summary
| 0H22 fundamental statistics | |
|---|---|
| Market cap | SEK 2.04b |
| Earnings (TTM) | -SEK 291.95m |
| Revenue (TTM) | SEK 254.29m |
Is 0H22 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H22 income statement (TTM) | |
|---|---|
| Revenue | SEK 254.29m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 254.29m |
| Other Expenses | SEK 546.25m |
| Earnings | -SEK 291.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | -4.44 |
| Gross Margin | 100.00% |
| Net Profit Margin | -114.81% |
| Debt/Equity Ratio | 0% |
How did 0H22 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 14:07 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioInvent International AB (publ) is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |